jhv1blz5 wrote: The article validated SOA as an IT architecture paradigm that can be leveraged in many ways. Taking data storage, scalability and application performance to a nifty level using SOA Application Grid infrastructure will no doubt enhance data and application performance on Oracle architecture platforms, it also has the promise of a cost effective and efficient IT delivery model. The very benefits of SOA.
BOSTON, MA -- (MARKET WIRE) -- 04/17/07 -- On Tuesday, May 1, at 6:00 p.m. EDT, during a
live interactive broadcast on www.OR-Live.com, physicians from Children's
Hospital Boston's Vascular Anomalies Center (VAC) will discuss and diagnose
patients referred for the team's internationally recognized expertise. This
90-minute Webcast is part of Children's ongoing effort to bring advanced
care and technology to specialists and referring physicians around the
world and to educate patients and families about the latest and most
innovative medical treatments available.
Vascular
anomalies, which include vascular tumors such as infantile hemangioma,
and malformations, are commonly
misdiagnosed resulting in inadequate or inappropriate treatment. To ensure
the best outcome, patients with vascular anomalies require the combined
expertise of an experienced, interdisciplinary team of specialists.
The Vascular Anomalies Center at Children's Hospital Boston cares for the
largest clinical volume of patients with vascular anomalies in the world,
with more than 1200 patients evaluated annually. During the team's weekly
Vascular Anomalies Conference physicians, nurse practitioners and a social
worker from 17 different specialty areas review medical histories,
photographs, radiographic images and biopsies of cases sent by patients,
families and physicians from across the country and around the world. More
than 400 cases are evaluated annually in this conference.
In this Webcast, the VAC team will evaluate patients and try to provide
accurate diagnoses and treatment recommendations. They will also answer
questions e-mailed to them from physicians and families live. Types of
problems reviewed may include infantile hemangioma, kaposiform
hemangioendothelioma (KHE), venous malformation , lymphatic
anomalies, arteriovenous malformation (AVM), Blue rubber bleb nevus
syndrome, Proteus Syndrome,
Klippel-Trenauny syndrome and other rare disorders.
Co-directors of the Vascular Anomalies Center at Children's Hospital
Boston, John B. Mulliken, MD, and Steven J. Fishman, MD, and will lead the
conference and answer e-mail questions from viewers during the live
broadcast. They will also direct questions to their colleagues on the VAC
team.
Dr. Mulliken, director of the Craniofacial Center, plastic surgeon at
Children's and professor of Surgery at Harvard Medical School, is the
internationally recognized forefather of the field of vascular anomalies,
which developed following his classification system. He and his colleagues
in genetics have discovered three genes that cause familial vascular
malformations.
"Broadcasting our Vascular Anomalies Conference on the Web allows us to
share the combined expertise of an experienced team of specialists," says,
Dr. Fishman, general surgeon at Children's and associate professor of
Surgery at Harvard Medical School. Dr. Fishman specializes in vascular
anomalies of the internal organs with a focus on developing evaluation and
intervention techniques including innovative operative procedures for the
treatment of visceral vascular anomalies.
The Vascular Anomalies Center conducts research focused on the development
of new, more effective therapies and ways to prevent these anomalies. Basic
research in angiogenesis (new blood vessel formation) is conducted in the
laboratories headed by M. Judah Folkman, MD, the Vascular Anomalies
Center's Scientific Director and the Julia Dyckman Andrus Professor of
Surgery at Harvard Medical School. Investigators are focused on the cause
-- the trigger mechanism -- that initiates the growth of infantile
hemangiomas. Dr. Folkman, a participant in the Vascular Anomalies
Conference, will also be an integral part of this Webcast, available to
answer questions from viewers live.
Clinical research has resulted in new more effective treatments. For
example, the center's investigators were the first to use interferon in the
treatment of children with large life- or vision-threatening hemangiomas.
Interferon and other chemotherapeutic and antiangiogenic drugs are used by
the hematologist/oncologist on the VAC team, Dr. Giannoula Klement. Dr.
Mulliken has described a simple technique for removal of hemangiomas
leaving a smaller scar than with conventional methods. In addition, Dr.
Fishman has developed novel approaches to control intestinal bleeding
caused by certain intestinal vascular malformations, such as blue rubber
bleb nevus syndrome.
Many other members of the Vascular Anomalies Team will be participating in
this Webcast including Interventional Radiologists Ahmad Alomari, MD,
Darren B. Orbach, MD, PhD, and Horacio Padua, MD; Orthopedic
Surgeon-in-Chief James R. Kasser, MD, Gastroenterologist and director of
the G.I. Endoscopy Unit Victor L. Fox, MD; Oncologist Giannoula Klement,
MD; Pathologist Harry P.W. Kozakewich, MD; Radiologist Harriet J. Paltiel,
MD; and Nurse Practitioners Erin Ryan, RN, MSCPNP, and Mary Beth Sylvia,
MS, CFNP.